Key result
Cigarette smoke promotes endothelial dysfunction and atherosclerosis through reactive oxygen species, while smoking cessation therapies like bupropion achieve only a 30% therapeutic success rate.
Why the study?
Atherosclerosis from smoking involves complex toxic mixtures beyond nicotine, and effective treatments for definitive smoking cessation remain lacking.
This review highlights the complex molecular mechanisms by which smoking causes vascular damage and endothelial dysfunction, underscoring the ongoing need for more effective smoking cessation therapies.
Low bupropion success cautions reliance on existing cessation therapies; leaves open ROS-targeted strategies for endothelial protection.
Cigarette smoke is a complex mixture of about 7,000 different toxic substances, many of which are generated during the burning of the tobacco leaf, some in the gas phase and others in the particulate matter. The gas phase represents approximately 60% of the smoke from the burning of tobacco, 99% of this phase is composed of nitrogen, oxygen, carbon dioxide, carbon monoxide, hydrogen, argon, and methane. Atherosclerosis associated with smoking is not necessarily an effect of nicotine, but probably the joint action of the various constituents of cigarette smoke. ROS from the gas phase of tobacco contributes to the onset and progression of atherosclerosis. Bupropion and varenicline are used for smoking cessation despite the side effects; however, we are still far from effective treatment to assist the definitive discontinuation of the habit of smoking. This review discusses the main mechanisms associated with vascular damage from the smoking.
No takes yet. Share an insight, caveat, or question.
JC et al. (2022) conducted a review in Endothelial dysfunction and atherosclerosis associated with smoking. Smoking cessation therapies (Bupropion, Varenicline) was evaluated. Cigarette smoke promotes endothelial dysfunction and atherosclerosis through reactive oxygen species, while smoking cessation therapies like bupropion achieve only a 30% therapeutic success rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: